Milford-based SeraCare Life Sciences saw a net loss of $600,000 for the third quarter of the year, compared to a $700,000 loss for the same quarter last year.
SeraCare’s revenue for the quarter grew to $12.4 million from $12 million last year. The company reported “nominal sales” from therapeutic grade albumin products, used in tests for certain diseases, which brought in $1.4 million in Q3 2007. But the company said sales of other core manufactured products increased $1.2 million, or 16 percent.
SeraCare said it has been investing in research and development and sales and marketing to drive growth in its core businesses. It also noted that the company was relisted on the Nasdaq stock market during the third quarter.
